Broad-spectrum antimicrobial compositions based on combinations of taurolidine and protamine and medical devices containing such compositions
US-9220814-B2 · Dec 29, 2015 · US
Preventing biological tissue adhesion
US2023241294A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023241294-A1 |
| Application number | US-202318167864-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 12, 2023 |
| Priority date | Mar 18, 2016 |
| Publication date | Aug 3, 2023 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and materials for mitigating biological tissue adhesion are described herein. One method for mitigating adhesion to a biological tissue includes administering an effective amount of a self-assembling peptide solution to the biological tissue, wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions.
First claim
Opening claim text (preview).
1 - 49 . (canceled) 50 . A method for mitigating adhesion to a target area of a biological tissue or between biological tissues using a self-assembling peptide solution, the method comprising: administering an effective amount of the self-assembling peptide solution to a biological tissue at a surgical site, wherein the self-assembling peptide comprises (RADA) 4 (SEQ ID NO:11); wherein the self-assembling peptide is about 2.5% w/v of the solution; wherein the self-assembling peptide solution forms a hydrogel under physiological conditions; wherein the hydrogel mitigates adhesion to the biological tissue or of another biological tissue to the biological tissue at a surgical site; wherein the hydrogel assists in healing of areas in which a surgical procedure was performed; and wherein the biological tissue comprises intraperitoneum, cecum, and/or intestine. 51 . The method of claim 50 , wherein the effective amount of the self-assembling peptide solution is approximately 0.1 mL per 1 cm 2 to approximately 5 mL per 1 cm 2 of target area. 52 . The method of claim 50 , wherein the effective amount of the self-assembling peptide solution is approximately 1 mL per 1 cm 2 of target area. 53 . The method of claim 50 , wherein the hydrogel is formed before administering the self-assembling peptide solution to the target area, or wherein the hydrogel is formed after administering the self-assembling peptide solution to said target area. 54 . The method of claim 50 , wherein the self-assembling peptide solution further comprises a biologically active agent. 55 . The method of claim 50 , wherein the self-assembling peptide solution is substantially free of cells and/or drugs. 56 . The method of claim 50 , wherein the self-assembling peptide solution is administered in vivo. 57 . The method of claim 50 , wherein the biological tissue is human tissue.
Assignees
Inventors
Classifications
- A61L31/047Primary
Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046 · CPC title
Hydrogels or hydrocolloids · CPC title
Proteins; Polypeptides; Degradation products thereof · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2023241294A1 cover?
- Methods and materials for mitigating biological tissue adhesion are described herein. One method for mitigating adhesion to a biological tissue includes administering an effective amount of a self-assembling peptide solution to the biological tissue, wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a h…
- Who is the assignee on this patent?
- 3 D Matrix Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61L31/047. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Aug 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).